Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients

Fig. 1

Kaplan-Meier survival plots of mCRPC patients. The survival differences were compared: (1) between patients without CTC and those with CTCs (≥1) (A for PFS analysis and B for OS analysis); (2) between patients with low levels of NLR and those with high levels of NLR (C for PFS analysis and D for OS analysis); (3) between patients with low levels of PLR and those with high levels of PLR (E for PFS analysis and F for OS analysis). Survival differences were compared with the log rank test, with P < 0.05 denoting significance. mCRPC: metastatic castration-resistant prostate cancer; CTC: circulating tumor cell; NLR: neutrophil-lymphocyte ratio; PLR: platelet-lymphocyte ratio; PFS: progression-free survival; OS: overall survival

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us